GAST and gastrin-producing neuroendocrine tumor: At the time of the second SASI test, the hepatic gastrinoma experienced suppressed production of gastrin granules due to the administration of octreotide acetate, so the serum IRG levels at the second SASI test might have been lowered by about 1% compared to those at the first SASI test.